In NSCLC, high levels of SLC7A11 are associated with advanced stage of disease and poor 5-year survival rates of patients.19 Moreover, SLC7A11-mediated metabolic reprogramming promoted the malignant behavior of NSCLC cells.20 Results of a further previous study revealed that inhibition of SLC7A11 reduced the chemoresistance of NSCLC to cisplatin;21 however, the specific regulatory mechanism underlying SLC7A11 in NSCLC remains to be fully elucidated. Here, SLC7A11 is linked to non-small cell lung carcinoma.